A 64-year-old male patient, performance status ECOG 1, with history of primary sclerosing cholangitis and advanced iCCA presents progressive disease on first line therapy with gemcitabine/cisplatin (GemCis) + durvalumab. A biopsy in the initial diagnostic assessment showed no IDH mutation but a re-arrangement of FGFR2.